ERBB2 and lymphoma: The chimeric receptor was successfully expressed by lentiviral transduction on T cell surface of a healthy donor, and ADCC activity was reported against CD20+ lymphoma, Her2/neu+ breast cancer and T-cell leukemia cell lines coated with rituximab, trastuzumab, and mogamulizumab (Mog), respectively.